Healthcare · NSE/BSE: ZYDUSLIFE
Zydus Lifesciences Limited
Pharmaceuticals
Market Cap ₹1.08L Cr
Verdict: High
Quality Scores
Multi-Bagger
74/100
Compounder Quality
89/100
Management Credibility
88/100
Governance
85/100
Cash Flow Quality
92/100
AI Summary
Zydus Lifesciences (formerly Cadila Healthcare) has evolved into a powerhouse in the Indian pharmaceutical sector, demonstrating significant scaling from a modest base to over ₹27,000 Cr in revenue by FY26. The company maintains a robust presence across India formulations and the US generics market, historically pivoting from a mid-sized player to a top-tier global pharmaceutical entity. Financial performance over the last decade shows a consistent CAGR in revenue and profits around 11-12%, with a significant acceleration in the last three years (32% profit growth). The balance sheet has been…
Top Opportunities
- Consistent 10-year ROE of 20%
- Aggressive debt reduction in last 3 years
- Expansion of Operating Margins to 28%
Top Risks
- Frequent USFDA regulatory observations/Warning Letters
- High inventory days (200+) leading to working capital lock-up
- Increasing Debtor Days (97 in Mar 2024)
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.